Analysis Group Consultants to Present at ISPOR Europe 2026
Event: ISPOR Europe 2026 Dates: 8–11 November 2026 Host: ISPOR – The Professional Society for Health Economics and Outcomes Research Location: Vienna, Austria
Analysis Group, a global leader in health economics and outcomes research (HEOR), epidemiology, and market access, will present an educational symposium and share five research posters at ISPOR Europe 2026, which will be held at the Austria Center Vienna in Vienna, Austria.
Managing Principal Eric Wu, Principal Jimmy Royer, and Maxime Leroux (DMined Consulting Services) will present an educational symposium titled “Advancing Evidence-Based Medicine with Generative AI.” The symposium will explore the frontiers of GenAI in evidence-based medicine and precision health, highlighting methodological advances and practical applications. The presenters will demonstrate how heterogeneous data sources can be enriched and integrated to generate context-specific yet broadly relevant insights and support precision health research.
The symposium will also showcase how GenAI and digital twins can support a continuum of evidence generation, from modeling disease progression and long-term treatment effects to individualized prediction and enhanced clinical trial design, while strengthening how evidence is generated and interpreted for health care decision making. The symposium will be held on Monday, November 9, at 12:15 p.m.
Further details on this presentation and Analysis Group’s posters are available in our ISPOR Europe 2026 Presentation Guide.
Associated People
Jimmy Royer
PrincipalDr. Royer applies a broad range of quantitative tools to address client needs in data science, statistics, HEOR, finance, intellectual property, competition policy, and antitrust cases in the United States, Canada, and the EU. His recent work includes predicting the potential future onset of rare or undiagnosed conditions with machine learning models; predicting whether patents would be considered essential to technological standards if challenged in courts; valuing patents in the communications industry; evaluating damages related to product defects; analyzing investment guidelines in securities lending suits; addressing allegations of monopolization in major antitrust cases involving high tech firms; and supporting many academic experts on mutual fund market timing and excess fee cases. In addition, Dr. Royer has conducted extensive academic research and coauthored books and papers on topics such as using new AI advances in HEOR; predicting treatment resistance in tuberculosis, using machine learning algorithms in propensity score models; measuring the impact of ESO backdating on shareholders’ wealth; analyzing mutual fund pricing; analyzing antitrust limit pricing; valuing private investments for hospitals in Canada; determining the impact of hypertension therapies on mortality; and comparing unemployment compensation in different countries.